Antibody-drug Conjugates (ADCs) represent a potent therapeutic for targeted delivery of toxins to specific cell types. ADCs are composed of a moncolonal antibody (mAb) conjugated to a drug molecule via a linker. The use of mAbs results in the delivery of the cytotoxic payload to only the targeted cell type, and because of this ADCs have shown promise as an effective site-specific cancer therapy (1). Two ADC’s, Kadcylca ® (Genentech/Roche) and Adcetris ® (Seattle Genetics), have been approved by the FDA for use in Her2-positive metastatic breast cancer and relapsed Hodgkin’s Lymphoma or systemic anaplastic large cell lymphoma respectively.
There are more than 50 ADC candidates currently in clinical development, with more than 10 entering Phase II and III clinical trials. However, large-scale production of ADCs has been hampered by a number of factors, including the lack of efficient and consistent conjugation of antibody to the desired toxic compound; inconsistent antibody internalization; and unstable linkers that release the toxin prior to the arrival at the target tissue. MabPlex offers state of the art solutions to these problems to allow robustly, large-scale production of ADCs with predictable and consistent conjugation efficiency using a variety of linkers.
If you’re interested in learning more about MabPlex and their solutions to large-scale ADC production challenges, visit them at Booth 11 at Americas Antibody Congress 2017 , May 23-24 at the Hilton San Diego Resort and Spa in San Diego, CA